The FDA has introduced a pilot commissioner’s national priority voucher program designed to shorten review timelines for biotech companies by one to two months. FDA Commissioner Martin Makary detailed these initiatives at the 2025 Biotechnology Innovation Organization International Convention, emphasizing efforts to enhance competitiveness amid global challenges and streamline regulatory processes while maintaining scientific rigor.